by Bob Yirka, Medical Xpress Reducing the activity of the enzyme LRRK2 in the human brain with DNL201 may help protect cells in the midbrain and treat Parkinson’s disease. Credit: P. Lewis, et al. A large team of researchers from Denali Therapeutics, working with colleagues from multiple entities in the U.S. and one in Canada,...
by University of California, Irvine “Although L-dopa remains the gold standard for Parkinson’s treatment, as the disease progresses, efficacy decreases, requiring higher and more frequent doses, which increases the risk of dyskinesia,” says the study’s co-corresponding author Amal Alachkar, Ph.D., associate professor of teaching in UCI’s Department of Pharmaceutical Sciences. “Our study indicates that L-dopa...
The shells of crustaceans and wood waste such as branches pruned from trees usually end up in landfills. These waste materials get a new lease of life to become nutritional supplements and medicine, with the help of this new process. Associate professor Yan Ning and assistant professor Zhou Kang from NUS Chemical and Biomolecular Engineering led the...
